Merck to acquire Pandion Therapeutics for $60 per share in cash, 140% premium. https://www.businesswire.com/news/home/20210225005318/en/Merck-to-Acquire-Pandion-Therapeutics Note PAND has only 30M shares outstanding, hence such a premium. BO of AMRN, if any, won't be at such a premium, due to over 400M shares outstanding for AMRN, thanks to JT and his bloated management tem.
Market Data 
Markets 
AI
